Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.

Griet HosteK PunieH WildiersB BeuselinckI LefeverE Van NieuwenhuysenS N HanP BertelootN ConcinR SalihiI VergoteP Neven

Published in: Breast cancer research and treatment (2018)

Palbociclib in combination with endocrine therapy shows an unexpectedly high CBR and favorable safety profile in heavily pretreated endocrine-resistant estrogen receptor-positive, HER2-negative MBC patients.

Keyphrases

estrogen receptor
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
squamous cell carcinoma
small cell lung cancer
metastatic breast cancer
young adults
patient reported outcomes
mesenchymal stem cells
cell therapy
replacement therapy